N. Nakagaki

发表

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by &agr;1 Nicotinic Acetylcholine Receptor–Mediated Activation in PC9 Cells

Y. Nakanishi, K. Takayama, Kentaro Tanaka, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

K. Goto, K. Nishio, Y. Nakanishi, 2019, The oncologist.

A new cancer cell detection method using an infectivity-enhanced adenoviral vector.

Y. Nakanishi, M. Fujita, K. Takayama, 2012, Asian Pacific journal of cancer prevention : APJCP.

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).

Y. Ichinose, K. Sugio, M. Shimada, 2019, Lung cancer.

Inhalative administration of insulin using a new bubble jet atomization device.

Y. Nakanishi, H. Inoue, S. Fukuyama, 2011, Fukuoka igaku zasshi = Hukuoka acta medica.

Vascular endothelial growth factor promoter‐based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma

M. Fujita, K. Takayama, J. Uchino, 2016, Cancer science.

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

K. Nishio, Y. Nakanishi, K. Azuma, 2019, Cancer.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

Y. Nakanishi, K. Azuma, I. Okamoto, 2017, Oncotarget.

Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication

Y. Nakanishi, K. Takayama, J. Uchino, 2009, Cancer Gene Therapy.

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

M. Seike, K. Sugio, Y. Nakanishi, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

Y. Nakanishi, K. Azuma, I. Okamoto, 2017, Oncotarget.

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

M. Seike, K. Sugio, Y. Nakanishi, 2019, The oncologist.

Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer

Y. Nakanishi, H. Sasaki, I. Okamoto, 2019, AntiCancer Research.

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

M. Seike, K. Sugio, Y. Nakanishi, 2020, The oncologist.